FAKTOR OPTIONSSCHEIN - NOVO-NORDISK B | Delayed Deutsche Boerse AG 04:20:54 2024-06-03 am EDT | ||
| 10.98 EUR | -13.13% |
|
| 1 month | -19.49% | ||
| 3 months | -10.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 10.98 | -13.13% |
| 24-05-31 | 12.64 | +10.01% |
| 24-05-30 | 11.49 | +19.31% |
| 24-05-29 | 9.63 | -6.87% |
| 24-05-28 | 10.34 | -10.63% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 04:20 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PC14N0 |
| ISIN | DE000PC14N08 |
| Date issued | 2022-08-31 |
| Strike | 916.9 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 311.8 € |
|---|---|
| Lowest since issue | 1.36 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
